Sharon Fernandez

Sharon Fernandez

Auto-generated profile, based on publicly available information

Sharon Fernandez

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, the United Kingdom of Great Britain and Northern Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
KFKavi Fatania
Kavi Fatania
RFRussell Frood
Russell Frood
MTMarcus Tyyger
Marcus Tyyger
GMGarry McDermott
Garry McDermott
SFSharon Fernandez
Sharon Fernandez
SCStuart Currie
Stuart Currie
Anti-1-amino-3-18fluorine-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) positron emission tomography (PET) shows preferential glioma uptake but there is little data on how uptake correlates with post-contrast T1-weighted (Gd-T1) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) activity during adjuvant treatment. This pilot study aimed to compare 18F-fluciclovine PET, DCE-MRI and Gd-T1 in patients undergoing chemoradiotherapy for glioblastoma (GBM), and in a parallel pre-clinical GBM model, to investigate correlation between 18F-fluciclovine uptake, MRI findings, and tumour biology. 18F-fluciclovine-PET-computed tomography (PET-CT) and MRI including DCE-MRI were acquired before, during and after adjuvant chemoradiotherapy (60 Gy in 30 fractions with temozolomide) in GBM patients. MRI volumes were manually contoured; PET volumes were defined using semi-automatic thresholding. The similarity of the PET and DCE-MRI volumes outside the Gd-T1 volume boundary was measured using the Dice similarity coefficient (DSC). CT-2A tumour-bearing mice underwent MRI and 18F-fluciclovine PET-CT. Post-mortem mice brains underwent immunohistochemistry staining for ASCT2 (amino acid transporter), nestin (stemness) and Ki-67 (proliferation) to assess for biologically active tumour. 6 patients were recruited (GBM 1–6) and grouped according to overall survival (OS)—short survival (GBM-SS, median OS 249 days) and long survival (GBM-LS, median 903 days). For GBM-SS, PET tumour volumes were greater than DCE-MRI, in turn greater than Gd-T1. For GBM-LS, Gd-T1 and DCE-MRI were greater than PET. Tumour-specific 18F-fluciclovine uptake on pre-clinical PET-CT corresponded to immunostaining for Ki-67, nestin and ASCT2. Results suggest volumes of 18F-fluciclovine-PET activity beyond that depicted by DCE-MRI and Gd-T1 are associated with poorer prognosis in patients undergoing chemoradiotherapy for GBM. The pre-clinical model confirmed 18F-fluciclovine uptake reflected biologically active tumour.

21 June 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
NGN. Gleim
N. Gleim
ATA. Turcas
A. Turcas
GMG. Minniti
G. Minniti
AGAnca-Ligia Grosu
Anca-Ligia Grosu
TKTomas Kazda
Tomas Kazda
CSClemens Seidel
Clemens Seidel
Preservation of neurocognitive function is gaining importance for patients with brain metastases (BM). Several methods of neuroprotection in radiotherapy of BM have been developed and tested in prospective clinical trials, including stereotactic radiotherapy (SRT), hippocampal-sparing whole-brain radiotherapy (HS-WBRT) and concomitant memantine. The present analysis aimed to assess the current treatment patterns in European countries. We distributed an online survey among radiation oncologists (ROs) registered within the European Society for Radiotherapy and Oncology (ESTRO). Questions included characteristics of treatment centers and institutional standard operating procedures, focusing on the use of neuroprotective measures. The survey was completed by 234 ROs from 31 countries. WBRT is the preferred treatment modality over SRT for 4-5 BM for 18 % and for 6-10 BM for 53 % of ROs. While HS-WBRT is generally offered by most ROs (85 %), only a minority apply the technique regularly (25 %), and prescription parameters vary considerably. Concomitant memantine is prescribed by 30 % of ROs. Besides concerns about available evidence, limited staff capacity and reimbursement issues constitute frequent obstacles. Boost treatments as part of WBRT are rarely performed on a regular basis (22 %). Prognostic scores are used by a majority of ROs, while cognitive tests are not. There were significant differences between higher- and lower-income countries, and between university hospitals and other centers. There is considerable heterogeneity regarding neuroprotective radiotherapy approaches in European countries and regular application is limited. Besides clinical trial results, improved technical availability and reimbursement might be required to improve their utilization for BM treatment.

10 April 2025 in Journal of Patient Experience
Verified
Journal Article
Open access
SFSharon Fernandez
Sharon Fernandez
SSSusan C Short
Susan C Short
FBFlorien Boele
Florien Boele
Chemoradiotherapy treatment for glioblastoma causes acute and long-term toxicities, negatively impacting quality of life. Patients require evidence-based, yet understandable information regarding treatment-induced toxicities to increase preparedness for treatment. A repeat cross-sectional, qualitative design was used. Semi-structured interviews were conducted with glioblastoma patients and their caregivers at set timepoints: prior to (T1), during (T2), and post (T3) chemoradiotherapy. Interviews were recorded, transcribed verbatim, and thematically analyzed. In total, 19 patients and 12 caregivers were interviewed. Three main themes emerged. (1) Navigating information materials, (2) Lack of awareness and understanding of chemoradiotherapy-induced toxicities, (3) The actual experience and impact of chemoradiotherapy toxicities. There is a discrepancy between the treatment information materials provided and patient expectation and experience of toxicities during and after chemoradiotherapy. Current informational resources do not adequately prepare patients or caregivers for the reality of treatment-induced toxicities. Better tailored resources are needed as individual needs fluctuate across the treatment trajectory. Further cross-center investigation is required to understand how we best create a personalized information pathway for glioma patients.

9 May 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
ATAndrada Turcas
Andrada Turcas
AWAoife Williamson
Aoife Williamson
NGNils Gleim
Nils Gleim
TKTomas Kazda
Tomas Kazda
SFSharon Fernandez
Sharon Fernandez
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
Radiotherapy (RT) represents a cornerstone treatment for brain and head-and-neck (H&N) tumours. Radiation-associated neurocognitive decline (ND) is a clinically relevant late effect. Dose-response relationships for ND and the contribution of specific brain substructures are incompletely characterized. This systematic review summarises current evidence on neurocognitive assessments, ND dose-volume predictors, and imaging correlates of radiation-induced injury. A systematic search of PubMed and Scopus/Embase identified studies reporting neurocognitive outcomes, dose-effect relationships, and imaging biomarkers in adults with brain and H&N tumours. Following PRISMA methodology, study selection was performed independently by three reviewers. Data on study design, RT characteristics, neurocognitive testing, and imaging findings were extracted and synthesised descriptively. Twenty-eight studies met the inclusion criteria. Most were small cohorts with heterogeneous neurocognitive testing. Verbal Learning Tests and Trail Making Test A/B were the most frequently used. ND was reported in 17 studies, with variable incidence (21%-79%). Memory was the most consistently affected domain and showed the strongest association with hippocampal dose. Higher doses to the temporal lobes, thalamus, amygdala, cerebellum, and corpus callosum were associated with deficits in executive function, processing speed, attention, and motor coordination. Advanced imaging demonstrated dose-dependent atrophy, white-matter disruption, perfusion changes, and metabolic alterations correlating with ND. ND after brain irradiation appears to be associated with dose-dependent injury involving multiple brain structures beyond the hippocampus. Current exploratory evidence requires validation in larger prospective studies with standardized neurocognitive assessment, imaging protocols, and long-term follow-up to refine dose constraints and improve neurocognitive preservation.


16 September 2025 in Radiography
Verified
Journal Article
Closed access
SFS. Fernandez
S. Fernandez
KCK. Cox
K. Cox
DFDanielle Fairweather
Danielle Fairweather